TOL.ST
Toleranzia AB [TOL.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TOL.ST Stock Summary
Top 10 Correlated Stocks
TOL.ST
In the News
TOL.ST Financial details
Company Rating
-
Market Cap
107.23M
Income
-7.46M
Revenue
39.8M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
02 Nov 2020
P/E
-7.08
Forward P/E
-
PEG
3.18
P/S
-
P/B
0.35
P/C
-
P/FCF
-1.64
Quick Ratio
4.28
Current Ratio
4.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-26.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-35.71%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
1.04%
-
-
-
-
SMA20
-
SMA50
-32.79%
SMA100
-28.07%
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-6%
ROC
0.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.345-1.025
52W High
-
52W Low
-
RSI
50.35
Rel Volume
0.54
Avg Volume
138.21K
Volume
74.49K
Perf Week
1.96%
Perf Month
28%
Perf Quarter
-22.1%
Perf Half Y
-18.75%
-
-
-
-
Beta
1.313
-
-
Volatility
0.01%, 0.03%
Prev Close
0.97%
Price
0.416
Change
-0.95%
Company Profile
- Volume Average 138.21K
- Market Capitalization 107.23M
- Employee 12
- CEO Ms. Charlotte Fribert
- Headquarters Gothenburg,SE
- IPO Date 2015-12-16
-
Website
https://www.toleranzia.com 
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, the company develops tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was founded in 2011 and is headquartered in Gothenburg, Sweden.
